Location History:
- London, GB (1996 - 1999)
- 3065 NH Rotterdam, NL (1999)
- Rotterdam, NL (1998 - 2024)
Company Filing History:
7 out of 17 
5 out of 259 
4 out of 5 
Years Active: 1996-2024
Title: Franklin Gerardus Grosveld: Innovations in Antibody Production
Introduction
Franklin Gerardus Grosveld is a notable inventor based in Rotterdam, Netherlands, and has made significant contributions to the field of antibody production through his innovative research. With an impressive portfolio of 18 patents, Grosveld's work reflects a deep understanding of genetic engineering and its applications in immunology.
Latest Patents
Among his latest patents, Grosveld focuses on groundbreaking methods for antibody production. One of his patents involves a transgenic non-human mammal that contains heterologous lambda light chain gene locus and/or kappa light chain gene locus. This innovative approach allows for the rearrangement of immunoglobulin heavy and light chain genes, which are expressed in B-cells upon antigen challenge. In addition, he has developed a method for producing heavy chain only antibodies in transgenic mammals, which involves a mammal containing a heterologous heavy chain gene locus, capable of generating soluble heavy chain only antibodies and antigen-binding fragments following immunization.
Career Highlights
Franklin Gerardus Grosveld has collaborated with reputable institutions such as Erasmus University Medical Center and the Medical Research Council throughout his career. His work at these institutions has positioned him at the forefront of research in biotechnology and genetic engineering.
Collaborations
Grosveld has worked alongside esteemed colleagues, including Roger Kingdon Craig and Richard Wilhelm Janssens. Their combined expertise has undoubtedly propelled significant advancements in their research endeavors, particularly in the fields of molecular biology and immunology.
Conclusion
Franklin Gerardus Grosveld's innovations in antibody production exemplify the intersection of genetic engineering and therapeutic advancement. With a total of 18 patents, his contributions continue to influence the scientific community and pave the way for future developments in antibody therapies. His work is a testament to the impact of dedicated research and collaboration in addressing complex medical challenges.